Is Vaxart Inc (vxrt) a good stock to buy?
Mar 28, 2022 · Our Ai stock analyst implies that there will be a negative trend in the future and the VXRT shares are not a good investment for making money. Since this share has a negative outlook we recommend looking for other projects instead to build a portfolio.
How often are the vxrt stock predictions updated?
Dec 01, 2021 · VXRT stock is down 9% today as it appears to be leveling off from its recent highs. The drop could be due to a certain fast-talking CNBC figurehead. Source: Ascannio / Shutterstock.com
Will there be a reversal in the vxrt?
Find the latest Vaxart, Inc. (VXRT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
What is the target price for vxrt?
Apr 14, 2022 · VXRT Vaxart Inc — Stock Price and Discussion | Stocktwits. Vaxart Inc NASDAQ Updated Apr 14, 2022 11:59 PM. VXRT 4.66 0.22 (4.51%) Post-Market 0.00 (0.00%) 76,017. Key Data. 52wk Low 3.91. 52wk High 11.11.
Why is VXRT going down?
The biotech's stock has been sliding hard over the past month and half for two related reasons: Vaxart's oral COVID-19 vaccine pill may not be on the market until the pandemic is starting to fade from the daily news cycle.Oct 7, 2021
Is VXRT a good stock to buy?
Is VAXART Stock a good buy in 2022, according to Wall Street analysts? The consensus among 4 Wall Street analysts covering (NASDAQ: VXRT) stock is to Strong Buy VXRT stock.
Will vaxart go up?
The 4 analysts offering 12-month price forecasts for Vaxart Inc have a median target of 11.50, with a high estimate of 18.00 and a low estimate of 7.00. The median estimate represents a +159.59% increase from the last price of 4.43.
Why is VXRT stock up?
Shares of biotech Vaxart (NASDAQ: VXRT) soared back in 2020 following enthusiasm that the company would eventually become a leader in the COVID-19 vaccine market.
What is vaxart future?
According to the 4 industry analysts covering Vaxart, the consensus is that breakeven is near. They expect the company to post a final loss in 2022, before turning a profit of US$6.4m in 2023. The company is therefore projected to breakeven around 2 years from today.Sep 14, 2021
"Should I invest in Vaxart stock?" "Should I trade "VXRT" stock today?"
According to our live Forecast System, Vaxart Inc stock is a bad long-term (1-year) investment *.
What is the Vaxart stock price / share price today?
The Vaxart stock price is 4.240 USD today.
Will VXRT stock price drop / fall?
Yes. The Vaxart stock price may drop from 4.240 USD to 4.235 USD...
Will VXRT stock price grow / rise / go up?
No. See above .
Will VXRT stock price crash?
According to our analysis, this can happen.
Will Vaxart stock price hit 10 USD price in a year?
Not within a year. See above .
Will Vaxart stock price hit 20 USD price in a year?
Not within a year. See above .
Will Vaxart stock price hit 50 USD price in a year?
Not within a year. See above .
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
Vaxart, Inc.'s (NASDAQ:VXRT) Shift From Loss To Profit
When I first wrote about Vaxart (NASDAQ:VXRT) stock on Aug. 10, I was completely enamored by the clinical-stage biotech company’s attempts to bring an oral Covid-19 vaccine to the market.
Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
Vaxart, Inc. ( NASDAQ:VXRT ) is possibly approaching a major achievement in its business, so we would like to shine...
Vaxart Announces Creation of New Scientific and Clinical Advisory Board
Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington, Ph.D., to the company's board of directors. Dr. Cherrington is an experienced life science executive with extensive insights into taking drugs through the development process to commercialization.
Is the Options Market Predicting a Spike in Vaxart (VXRT) Stock?
Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board.
Why Shares of Vaxart Are Soaring Today
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
VAXART, INC. (VXRT) Reports Q2 Loss, Misses Revenue Estimates
Shares of clinical-stage vaccine developer Vaxart (NASDAQ: VXRT) are up again today, gaining 12.34% to $9.83 apiece as of 2:30 p.m. EDT. The stock is up 21% over the past five trading days due to greater capital inflows after the company released encouraging second-quarter earnings on Aug. 5.
VXRT Target Price
VAXART, INC. (VXRT) delivered earnings and revenue surprises of 7.14% and -79.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Vaxart Inc ( VXRT ) Stock Market info
VXRT price target in 14 days: 9.604 USD* upside and 8.364 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Vaxart Inc ( VXRT ) Stock Price Prediction, Stock Forecast for next months and years
Recommendations: Buy or sell Vaxart stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vaxart share forecasts, stock quote and buy / sell signals below. According to present data Vaxart's VXRT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).
Vaxart earnings
Below you will find the price predictions for 2021, 2022, 2023, 2024, 2025, 2026.
VXRT COVID-19 vaccine candidate
While Vaxart is a clinical-stage biotech company, it's also making revenues from some of the products. The company reported revenues of $4.05 million in 2020, which were less than half of what it reported in 2019.
VXRT stock forecast
On May 5, Sean Tucker, Vaxart’s Chief Scientific Officer, presented at a virtual event organized by the World Vaccine Congress Washington. He offered insights on the trial results of the company’s oral vaccine candidate and compared it with vaccines from Moderna and Pfizer.
COVID-19 vaccine stocks are dropping
The forecast for VXRT stock looks positive. According to the estimates compiled by CNN Business, VXRT has a median target price of $11.5, which is a 56 percent premium over the current prices. Its highest and lowest target prices are $13 and $10, respectively. The stock is covered by only two analysts and both of them have a buy rating.
Will VXRT stock rise or fall?
Meanwhile, we’ve seen a drop in stocks of many companies that are developing vaccines or drug candidates for COVID-19. On May 5, Cocrystal fell sharply after announcing a discounted stock sale.
What risk does Vaxart face
VXRT stock might have bottomed and could rise from these levels. Like all clinical-stage biotech companies, VXRT is a speculative play. However, what I find particularly interesting about the company is the vaccine administration which is oral rather than through a syringe. This would help take away the vaccine hesitancy in some people.
The company released preliminary first-quarter results
Several countries including India are pushing for an IPR waiver for COVID-19 vaccines. This would help scale up production and lower costs. However, that might be a challenge for companies like Vaxart since it might risk being late to the game. That said, after the crash, the risk-reward dynamics look favorable for Vaxart stock.
What happened
A Fool since 2019, Prosper's writing focuses primarily on the healthcare sector. Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
So what
Shares of Vaxart ( NASDAQ:VXRT), a clinical-stage biotech focused on the development of orally administered vaccines, were down by 10.7% on Tuesday. The market is responding to the company's corporate update, which previewed Vaxart's financial results for the first quarter.
Now what
In its corporate update, the company said it expects to release additional data "within days" on its pre-clinical trial testing several potential COVID-19 vaccines.
Vaxart's Stock Price And Volume Action
Vaxart's stock is still up by more than 800% year to date. With the company racing to develop a vaccine for COVID-19, investors are hopeful that it will make a fortune off of it, and reward its shareholders in the process. Whether the biotech company can pull that off, however, remains highly unlikely.
Why It's Moving
Vaxart's (NASDAQ: VXRT) stock has been falling Wednesday, down 56.26% to a price of $10.21. Wednesday the stock has been traded at a volume of 26.93 million, about 193.74% of its recent 30-day volume average of 13.90 million.
Further Analysis of Recent Price Action
Benzinga Pro's real-time breaking news service shows some insight into what is affecting shares: Vaxart shares are trading lower after the company reported preliminary data from a Phase 1 clinical trial evaluating its oral COVID-19 tablet vaccine candidate.
Signals & Forecast
The moving average price of the stock over the past 50 days was $7.78 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $24.9 and as low as $0.96.
Support, Risk & Stop-loss
There are few to no technical positive signals at the moment. The Virtu Financial stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Virtu Financial stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
